Spectrum of epstein-barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation

Transplantation

Volumn 96, Issue 6, 2013, Pages 560-566

  Xuan, Li ^a   Jiang, Xinmiao ^a   Sun, Jing ^a   Zhang, Yu ^a   Huang, Fen ^a   Fan, Zhiping ^a   Guo, Xutao ^a   Dai, Min ^a   Liu, Can ^a   Yu, Guopan ^a   Zhang, Xian ^a   Wu, Meiqing ^a   Huang, Xiaojun ^b   Liu, Qifa ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Epstein Barr virusYassociated disease; Rituximab; Spectrum

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FOSCARNET; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXIC T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; ENCEPHALITIS; EPSTEIN BARR VIRUS INFECTION; FEMALE; FEVER; FOLLOW UP; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; INCIDENCE; LUNG BIOPSY; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MYELITIS; OVERALL SURVIVAL; PNEUMONIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHINA; DISEASE PROGRESSION; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84884819147     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31829d38af     Document Type: Article

References (38)

1. Menet A, Speth C, Larcher C, et al. Epstein-Barr virus infection of human astrocyte cell lines. J Virol 1999; 73: 7722.
2. Awaya N, Adachi A, Mori T, et al. Fulminant Epstein-Barr virus (EBV)- associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma. Leuk Res 2006; 30: 1059.
3. Kasahara Y, Yachie A, Takei K, et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 2001; 98: 1882.
4. Stewart JP, Egan JJ, Ross AJ, et al. The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1999; 159: 1336.
5. Kawa K. Epstein-Barr virusYassociated diseases in humans. Int J Hematol 2000; 71: 108.
6. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481.
7. Kutok JL,Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 2006; 1: 375.
8. Merlo A, Turrini R, Dolcetti R, et al. The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica 2010; 95: 1769.
9. Schober T, Framke T, Kreipe H, et al. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation 2013; 95: 240.
10. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569.
11. Bitan M. Epstein-Barr virus infection after stem cell transplantation: new concepts are needed both for the donor and the recipient. Clin Infect Dis 2006; 43: 896.
12. Reddy N, Rezvani K, Barrett AJ, et al. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 2011; 17: 591.
13. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56: 155.
14. Styczynski J, Einsele H, Gil L, et al. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11: 383.
15. Gross TG, Orjuela MA, Perkins SL, et al. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children?s Oncology Group report. Am J Transplant 2012; 12: 3069.
16. Tashiro Y, Goto M, Takemoto Y, et al. Epstein-Barr virus-associated enteritis with multiple ulcers after stem cell transplantation: first histologically confirmed case. Pathol Int 2006; 56: 530.
17. Wu XL, Liu QF. Epstein-Barr virus-associated diseases in allogeneic hematopoietic stem cell transplantation. J Hematol Oncol 2012; 5: A8.
18. Behr J, Schaefer M, Littmann E, et al. Psychiatric symptoms and cognitive dysfunction caused by Epstein-Barr virus-induced encephalitis. Eur Psychiatry 2006; 21: 521.
19. Liu QF, Fan ZP, Luo XD, et al. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation. Transpl Infect Dis 2010; 12: 284.
20. Kinch A, Oberg G, Arvidson J, et al. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis 2007; 39: 235.
21. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208.
22. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 4992.
23. Hou HA, Yao M, Tang JL, et al. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years? experience in a single institute. Bone Marrow Transplant 2009; 43: 315.
24. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein- Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364.
25. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359.
26. Kuehnle I, HulsMH, Liu Z, et al.CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502.
27. Wakiguchi H. Overview of Epstein-Barr virus-associated diseases in Japan. Crit Rev Oncol Hematol 2002; 44: 193.
28. Marzouk K, Corate L, Saleh S, et al. Epstein-Barr-virus-induced interstitial lung disease. Curr Opin Pulm Med 2005; 11: 456.
29. Xuan L, Huang F, Fan Z, et al. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stemcell transplantation for hematological malignancies. J Hematol Oncol 2012; 5: 46.
30. Liu Q, Xuan L, Liu H, et al. Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. Am J Hematol 2013. doi: 10.1002/ajh.23452.
31. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZVand EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43: 757.
32. Swerdlow SH, Webber SA, Chadburn A, et al. Post-transplant Lymphoproliferative Disorders. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008: 343.
33. Wagner HJ, Rooney CM, Heslop HE. Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 1.
34. Britton S, Andersson-Anvret M, Gergely P, et al. Epstein-Barr-virus immunity and tissue distribution in a fatal case of infectious mononucleosis. N Engl J Med 1978; 298: 89.
35. Vine LJ, Shepherd K, Hunter JG, et al. Characteristics of Epstein- Barr virus hepatitis among patients with jaundice or acute hepatitis. Aliment Pharmacol Ther 2012; 36: 16.
36. Fujimoto H, Asaoka K, Imaizumi T, et al. Epstein-Barr virus infections of the central nervous system. Intern Med 2003; 42: 33.
37. Boivin G. Diagnosis of herpesvirus infections of the central nervous system. Herpes 2004; 11: 48A.
38. Kalita J, Maurya PK, Kumar B, et al. Epstein Barr virus encephalitis: clinical diversity and radiological similarity. Neurol India 2011; 59: 605.